Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 74-92

  Murren, John R ^a   Beidler, David R ^a,b   Cheng, Yung Chi ^a  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; ETOPOSIDE;

CELL CYCLE S PHASE; CELL LINE; CONFERENCE PAPER; CYTOTOXICITY; DNA STRAND BREAKAGE; DOWN REGULATION; DRUG RESISTANCE;

EID: 0030464036     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26378.x     Document Type: Conference Paper

References (64)

1. LIU, L. F. 1989. DNA topoisomerase poisons as antitumor drugs. Ann. Rev. Biochem. 58: 351-375.
2. HSIANG, Y.-H. & L. LIU. 1988. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48: 1722-1726.
3. HSIANG, Y. H., R. HERTZBERG, S. HECHT & L. LIU. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase. I. J. Biol. Chem. 260: 14873-14878.
4. D'ARPA, P., C. BEARDMORE & L. LIU. 1990. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50: 6919-6924.
5. HOROWITZ, S. B. & M. HOROWITZ. 1973. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 33: 2834-2836.
6. LI, L., T. FRASER, E. OLIN & B. BHUYAN. 1973. Action of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 33: 2834-2836.
7. HUBERMAN, J. 1981. New views of the biochemistry of eucaryotic DNA replication revealed by aphidicolin, an unusual inhibitor of DNA polymerase alpha. Cell 23: 647-648.
8. ZHANG, H., P. D'ARPA & L. LIU. 1990. A model for tumor cell killing by topoisomerase poisons. Cancer Cells 2: 23-27.
9. HSIANG, Y., M. LIHOU & L. LIU. 1989. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49: 5077-5082.
10. RYAN, A., S. SQUIRES, H. STRUTT & R. JOHNSON. 1991. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res. 19: 3295-3300.
11. TSAO, Y.-P., P. D'ARPA & L. F. LIU. 1992. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: Altered regulation of p34cdc2/cyclin B. Cancer Res. 52: 1823-1829.
12. TOBEY, R. 1972. Effects of cytosine arabinoside, daunomycin, mithramycin, azacytidine, adriamycin, and camptothecin on mammalian cell cycle traverse. Cancer Res. 32: 2720-2725.
13. GALLO, R., J. WHANG-PENG & R. ADAMSON. 1971. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 46: 789-795.
14. DELBINO, G., P. LASSOTA & Z. DARZYNKIEWICZ. 1991. The S-phase cytotoxicity of camptothecin. Exp. Cell Res. 193: 27-35.
15. KHARBANDA, S., E. RUBIN, H. GUNJI, H. HINZ, B. GIOVANELLA, P. PANTAZIS & D. KUFE. 1991. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res. 51: 6636-6642.
16. STEWART, A., R. HERRERA & A. NORDHEIM. 1990. Rapid induction of c-fos transcription reveals quantitative linkage of RNA polymerase II and DNA topoisomerase I enzyme activities. Cell 60: 141-149.
17. DELBINO, G. & Z. DARZYNKIEWICZ. 1991. Camptothecin, teniposide, or 4′-(acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells. Cancer Res. 51: 1165-1169.
18. KAUFMANN, S. 1989. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 49: 5870-5878.
19. PANTAZIS, P., J. MENDOZA, J. EARLY, A. KOZIELSKI, E. NATELSON & B. GIOVANELLA. 1993. 9-nitro-camptothecin delays growth of U937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro. Eur. J. Haematol. 50: 81-89.
20. PANTAZIS, P., J. EARLY, J. MENDOZA, A. DEJESUS & B. GIOVANELLA. 1994. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res. 54: 771-776.
21. KANZAWA, F., Y. SUGIMOTO, K. MINATO, K. KASAHARA, M. BUNGO, K. NAKAGAWA, Y. FUJIWARA, L. F. LIU & N. SAIJO. 1990. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 50: 5919-5924.
22. CHANG, J. Y., L. A. DETHLEFSEN, L. R. BARLEY, B. S. ZHOU & Y. C. CHENG. 1992. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol. 43: 2443-2452.
23. GUPTA, R. S., R. GUPTA, B. ENG, R. B. LOCK, W. E. ROSS, R. P. HERTZBERG, M. J. CARANFA & R. K. JOHNSON. 1988. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 48: 6404-6410.
24. ANDOH, T., K. ISHI, Y. SUZUKI, Y. IKEGAMI, Y. KUSUNOKI, Y. TAKEMOTO & K. OKADA. 1987. Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. U.S.A. 84: 5565-5569.
25. SUGIMOTO, Y., S. TSUKAHARA, T. OH-HARA, L. F. LIU & T. TSURUO. 1990. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. 50: 7962-7965.
26. TAN, K. B., M. R. MATTERN, W.-K. ENG, F. L. MCCABE & R. K. JOHNSON. 1989. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst. 81: 1732-1735.
27. LIU L. F., P. DUANN, C.-T. LIN, P. D'ARPA & X. WU. Mechanism of action of camptothecin. Ann. N.Y. Acad. Sci. 803:44-49. This volume.
28. BEIDLER, D. R., J.-Y. CHANG, B.-S. ZHOU & Y.-C. CHENG. 1996. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res. 56: 345-353.
29. TSURUO, T., T. MATSUZAKI, M. MATSUSHITA, H. SAITO & T. YOKOKURA. 1988. Antitumor effect of CPT-11, a new derivative of camptothecin against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21: 71-74.
30. LIU, L. & K. MILLER. 1981. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from hela cell nuclei. Proc. Natl. Acad. Sci. U.S.A. 78: 3487-3491.
31. CHOMCZNSKI, P. & N. SACCHI. 1987. Single-step method of RNA isolation by acid-guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
32. ALSNER, J., J. Q. SVEJSTRUP, E. KJELDSEN, B. S. SORENSON & O. WESTERGAARD. 1992. Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function. J. Biol. Chem. 267: 12408-12411.
33. DANKS, M. K., K. E. GARRETT, R. C. MARION & D. O. WHIPPLE. 1996. Redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res. 56: 1664-1673.
34. BUCKWALTER, C. A., A. H. LIN, A. TANIZAWA, Y. G. POMMIER, Y.-C. CHENG & S. H. KAUFMANN. 1996. RNA synthesis inhibitors alter the subnuclear distribution of topoisomerase I. Cancer Res. 56: 1674-1681.
35. SUGIMOTO, Y., S. TSUKAHARA, T. OH-HARA, T. ISOE & T. TSURUO. 1990. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50: 6925-6930.
36. TAMURA, H. O., C. KOHCHI, R. YAMADA, T. IKEDA, O. KOIWAI, E. PATTERSON, J. D. KEENE, K. OKADA, E. KJELDSEN, K. NISHIKAWA & T. ANDOH. 1991. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res. 19: 69-75.
37. FERGUSON, P. J., M. H. FISHER, J. STEPHENSON, D. H. LI, B. S. ZHOU & Y. C. CHENG. 1988. Combined modalities of resistance in etoposide-resistant KB cell lines. Cancer Res. 48: 5956-5964.
38. ENG, W. K., F. L. MCCABE, K. B. TAN, M. R. MATTERN, G. A. HOFMANN, R. D. WOESSNER, R. P. HERTZBERG, & R. K. JOHNSON. 1990. Development of a stable camptothecin resistant subline of P388 leukemia with reduced topoisomerase I content. Mol. Pharmacol. 38: 471-480.
39. CRUMP, M., J. LIPTON, D. HEDLEY, J. G. SCOTT, D. SUTTON, A. KEATING, M. MINDEN, H. MESSNER & E. EISENHAUER. 1996. A phase I trial of sequential topotecan and etoposide in adult acute myeloid leukemia (AML). Proc. Am. Soc. Clin. Oncol. 15: 357 (abstract 1050).
40. COOPER, B. W., H. M. LAZARUS, R. CREGER, J. K. V. WILLSON, C. L. HOPPEL, S. J. BERGER, N. A. BERGER, D. M. GOSKY, B. MCGLOIN & S. L. GERSON. 1996. A phase I and pharmacodynamic study of sequential topotecan and etoposide (TE) in adult patients with refractory/relapsed leukemia. Proc. Am. Soc. Clin. Oncol. 15: 486 (abstract 1549).
41. CHATTERJEE, S., M. CHENG, D. TRIVEDI, S. PETZOLD & N. BERGER. 1990. Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. Cancer Comm. 1: 389-394.
42. SMITH, P., T. MAKINSON & J. WATSON. 1989. Enhanced sensitivity to camptothecin in ataxia-telangiectasia and its relationship with the expression of DNA topoisomerase I. Int. J. Rad. Biol. 55: 217-231.
43. SQUIRES, S., D. OATES, S. BOUFFLER & R. JOHNSON. 1992. Cockayne's syndrome fibroblasts are characterized by hypersensitivity to deoxyguanosine and abnormal DNA precursor pool metabolism in response to deoxyguanosine or ultraviolet light. Somat. Cell Molec. Gen. 18: 387-401.
44. STAMATO, T. & N. DENKO. 1990. Asymmetric field inversion gel electrophoresis: A new method for detecting DNA double-strand breaks in mammalian cells. Radiation Res. 121: 196-205.
45. DENKO, N., A. GIACCIA, B. PETERS & T. STAMATO. 1989. An inverted field inversion gel electrophoresis method for the separation of large DNA molecules. Analytica Biochem. 178: 172-176.
46. OBERHAMMER, F., W. JW, C. DIVE, I. MORRIS, J. HICKMAN, A. WAKELING, P. WALKER & M. SIKORSKA. 1993. Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J. 12: 3679-3684.
47. WALKER, P. R., C. SMITH, T. YOUDALE, J. LEBLANC, W. NEUGEBAUER & M. SIKORSKA. 1991. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res. 51: 1078-1085.
48. ROSEMANN, M., B. KANON, A. KONINGS & H. KAMPINGA. 1993. An image analysis technique for detection of radiation-induced DNA fragmentation after CHEF electrophoresis. Int. J. Rad. Biol. 64: 245-249.
49. BOULIKAS, T. 1991. Relation between carcinogenesis, chromatin structure and poly-(ADP-ribosylation). Anticancer Res. 11: 489-528.
50. BERGER, N., G. WEBER & A. KAICHI. 1978. Characterization and comparison of poly-(adenosine dephosphoribose) synthesis and DNA synthesis in nucleotide-permeable cells. Biochim. Biophys. Acta 519: 87-104.
51. KAUFMANN, S., S. MCLAUGHLIN, M. KASTAN, L. LIU, J. VARP & P. BURKE. 1991. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res. 51: 3534-3543.
52. HECK, M., W. HITTELMAN & W. EARNSHAW. 1988. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci. U.S.A. 85: 1086-1090.
53. SULLIVAN, D., M. LATHAM & W. ROSS. 1987. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse and Chinese hamster ovary cells. Cancer Res. 47: 3973-3979.
54. BEIDLER, D. R. & Y. C. CHENG. 1995. Camptothecin induction of a time- and concentration-dependent decrease of protein-linked DNA breaks and topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol. 47: 907-914.
55. TANIGUCHI, K., K. KOHNO, K. KAWANAMI, M. WADA, T. KANEMATSU & M. KUWANO. 1996. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res. 56: 2348-2354.
56. MURREN, J. R., S. ANDERSON, J. FEDELE, G. PIZZORNO, D. BELLIVEAU, D. ZELTERMAN, B. A. BURTNESS, I. TOCINO, D. BEIDLER & Y.-C. CHENG. 1997. Dose escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory malignancies. J. Clin. Oncol. In press.
57. ROWINSKY, E. K., L. B. GROCHOW, C. B. HENDRICKS, D. S. ETTINGER, A. A. FORASTIERE, L. A. HUROWITZ, W. P. MCGUIRE, S. E. SARTORIUS, B. G. LUBEIKO, S. H. KAUFMANN & R. C. DONEHOWER. 1992. Phase I and pharmacokinetic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol. 10: 647-656.
58. SALTZ, L., M. SIROTT, C. YOUNG, W. TONG, D. NIEDZWIECKI, Y. TZY-JYUN, Y. TAO, B. TROCHANOWSKI, P. WRIGHT, K. BARBOSA, F. TOOMASI & D. KELSEN. 1993. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl. Cancer Inst. 85: 1499-1507.
59. HAN, F.-S., G. E. DUTCHMAN, Y.-S. HUANG & Y. C. CHENG. 1985. Purification, characterization of monoclonal antibody of human DNA topoisomerase I. Proc. Am. Assoc. Cancer Res. 26: 3 (abstract 10).
60. SLICHENMYER, W. J., E. K. ROWINSKY, R. C. DONEHOWER & S. H. KAUFMANN. 1993. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85: 271-291.
61. BURRIS, H. A. I., A. HANAUSKE, R. JOHNSON, M. H. MARSHALL, J. G. KUHN, S. G. HISENBECK & D. D. VON HOFF. 1992. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl. Cancer Inst. 84: 1816-1820.
62. GIOVANELLA, B. C., H. R. HINZ, A. J. KOZIELSKI, J. S. J. STEHLIN, R. SILBER & M. POTMESIL. 1991. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. 51: 3052-3055.
63. VENDITTI, J. M. 1971. Treatment schedule dependency of experimentally active antileukemic (L1210) drugs. Cancer Chemother. Rep. 2: 35-39.
64. HOUGHTON, P. J., P. J. CHESHIRE, L. MYERS, C. F. STEWART, T. W. SYNOLD & J. A. HOUGHTON. 1992. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol. 31: 229-39.